Meta-analysis and trial sequential analysis of the therapy of Lanqin Oral Liquid combined with proton pump inhibitor for laryngopharyngeal reflux disease
Objective To systematically review the efficacy and safety of the therapy combined Lanqin Oral Liquid(LOL)with proton pump inhibitor(PPI)for the treatment of laryngopharyngeal reflux disease(LRD)to provide evidence-based medicine facts for clinical practice by a literature study.Methods Several databases were systematically searched for randomized controlled trials(RCT)on the therapy of LOL combined with PPI for its efficacy and safety in the treatment of LRD,including CNKI,CBM,PubMed,Embase,and Cochrane library.Then,retrieved trials were inputted into Microsoft Excel 2016 for information extraction,followed by Review Manager 5.3 treatment for meta-analysis and TSA0.9 software for trial sequential analysis.Results A total of 15 RCT studies were retrieved,with 1214 patients in total included.Meta-analysis showed that,when compared with simple PPI therapy alone,the combined therapy with LOL and PPI could improve the total effective rate on LRD[RR=1.23,95%CI(1.17,1.30),P<0.00001],reduced the RSI score[MD=-2.96,95%CI(-3.62,-2.30),P<0.00001]and RFS score[MD=-1.72,95%CI(-2.10,-1.33),P<0.00001],and shortened the time period required to relief throat symptoms[MD=-2.15,95%CI(-2.74,-1.57),P<0.00001].No serious adverse events were reported in any of the included trials Conclusion It has been shown from this review that the combined therapy of Lanqin Oral Liquid with proton pump inhibitor hold significant therapeutic effects on laryngopharyngeal reflux disease,with higher safety in clinical practice.However,more high-quality trials are needed to support its efficacy and safety.
NETL
NSTL
万方数据
